853687-38-4

Upstream product

• 16198-01-9 (-)-epicatechin pentaacetate 
• 490-46-0 (2R,3R)-2-(3,4-dihydroxyphenyl)-3,4-dihydro-1[2H]-benzopyran-3,5,7-triol 
• 853687-37-3 (-)-ECG-7TBS 
• 18162-48-6 tert-butyldimethylsilyl chloride 

Downstream Products

• 853687-43-1 2-[3,4-bis-(tert-butyl-dimethyl-silanyloxy)-phenyl]-5,7-bis-(tert-butyl-dimethyl-silanyloxy)-chroman-3-one 
• 853687-41-9 N-[(2R,3R)-2-(3,4-Dihydroxy-phenyl)-5,7-dihydroxy-chroman-3-yl]-3,4,5-trihydroxy-benzamide 
• 853687-48-6 2-[3,4-bis-(tert-butyl-dimethyl-silanyloxy)-phenyl]-5,7-bis-(tert-butyl-dimethyl-silanyloxy)-chroman-3-ylamine 
• 853687-47-5 2-[3,4-bis-(tert-butyl-dimethyl-silanyloxy)-phenyl]-5,7-bis-(tert-butyl-dimethyl-silanyloxy)-chroman-3-ylamine 
• 853687-45-3 benzyl-[2-[3,4-bis-(tert-butyl-dimethyl-silanyloxy)-phenyl]-5,7-bis-(tert-butyl-dimethyl-silanyloxy)-chroman-3-yl]-amine 
• 853687-44-2 benzyl-[2-[3,4-bis-(tert-butyl-dimethyl-silanyloxy)-phenyl]-5,7-bis-(tert-butyl-dimethyl-silanyloxy)-chroman-3-yl]-amine 
• 853687-46-4 [2-[3,4-bis-(tert-butyl-dimethyl-silanyloxy)-phenyl]-5,7-bis-(tert-butyl-dimethyl-silanyloxy)-chroman-3-yl]-[3,4,5-tris-(tert-butyl-dimethyl-silanyloxy)-benzyl]-amine 
• 853687-50-0 N-[2-[3,4-bis-(tert-butyl-dimethyl-silanyloxy)-phenyl]-5,7-bis-(tert-butyl-dimethyl-silanyloxy)-chroman-3-yl]-3,4,5-tris-(tert-butyl-dimethyl-silanyloxy)-benzamide 
• 853687-49-7 N-[2-[3,4-bis-(tert-butyl-dimethyl-silanyloxy)-phenyl]-5,7-bis-(tert-butyl-dimethyl-silanyloxy)-chroman-3-yl]-3,4,5-tris-(tert-butyl-dimethyl-silanyloxy)-benzamide 

Relevant academic research and scientific papers

Novel 3C-like protease inhibitor as well as preparation method and application thereof

The invention provides a novel 3C-like protease inhibitor which is 3 ", 4" - O - diacetyl -epicatechin trans-caffeic acid ester with a specific structure. The invention further provides a preparation method and application of the 3C-like protease inhibitor. The invention has the advantages that the compound 3 ", 4" - O - diacetyl - epicatechin trans-caffeic acid ester is designed and synthesized based on the structure of epicatechin; even when the concentration is low, the activity of 3C-like protease in the novel coronavirus can be obviously inhibited. The compounds can be used as 3C-like protease inhibitors and are used for preparing anti-novel coronavirus SARS-CoV - 2 infection drugs.

Preparation method and application of hydroxyl cinnamyl ester type catechin

The invention relates to a preparation method and application of hydroxyl cinnamyl ester type catechins. The hydroxyl cinnamyl ester type catechins comprise four catechins which are respectively namedas epicatechin trans-coumarate, epicatechin trans-caffeic acid ester, epigallocatechin trans-coumarate and epigallocatechin trans-caffeic acid ester. The hydroxyl cinnamyl ester type catechins are prepared by the following steps: carrying out four steps of full acetylation on epicatechin and epigallocatechin, removal of acetyl on phenolic hydroxyl, silanizing of phenolic hydroxyl and removal of 3-acetyl, then respectively esterifying with acetylated caffeic acid or coumaric acid acyl chloride, and removing a protecting group. The preparation method of the four catechins is simple and mild inconditions, and can be completed under general experimental conditions. The four hydroxycinnamyl ester type catechins have a certain inhibition effect on the activity of alpha-glucosidase, can be usedfor hypoglycemic drugs, and have important significance in the fields of agriculture and medicine.

PYRANS FOR USE IN THE TREATMENT OF INFECTION

There is provided a novel compound of the general formula (I), in which each R is hydrogen, aryl, C1-6 alkyl, trialkylsilyl, or acyl, each R1 is selected from hydroxy, C1-6 alkoxy and acyloxy; each R2 is H, Csu

Synthesis and antibacterial activity of hydrolytically stable (-)-epicatechin gallate analogues for the modulation of β-lactam resistance in Staphylococcus aureus

Hydrolytically more stable analogues of (-)-epicatechin gallate (ECg) have been synthesised from ECg where an amine or amide function has been substituted for the ester linkage that joins the C-ring with the galloyl D-ring. Sub-inhibitory concentrations (